
|Videos|March 14, 2019
Highlighting CAR T Cell Options for Relapsed/Refractory DLBCL
Author(s)David Miklos, MD
David Miklos, MD, discusses his advice for community oncologists treating patients with diffuse large B-cell lymphoma.
Advertisement
David Miklos, MD, associate professor of medicine at Stanford University, discusses his advice for community oncologists treating patients with diffuse large B-cell lymphoma (DLBCL).
Miklos says it is important to know that chimeric antigen receptor (CAR) T cells are effective and available for patients with relapsed/refractory DLBCL.
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Enfortumab Vedotin Plus Pembrolizumab Improves Survival in MIBC
2
Teclistamab/Daratumumab Earns FDA Priority Voucher for R/R Myeloma
3
Early Relapse Guides Use of CAR T vs Other Options in LBCL
4
FDA Fast-Tracks Muzastotug Combo in MSS Metastatic Colorectal Cancer
5








































